May 25, 2024

Advanced Glycation End Products Market is trending by increasing chronic disease prevalence

Advanced glycation end products (AGEs) are formed through the non-enzymatic reaction of reducing sugars with free amino groups in proteins. AGEs can alter the function and structure of proteins by disrupting enzymatic and regulatory function and cross-linking different molecules. AGEs accumulate slowly throughout life and at an accelerated rate in diabetes and aging leading to vascular and tissue damage.

AGEs are implicated in diabetes, cardiovascular diseases, neurodegenerative diseases, and kidney disease accelerating their progression through oxidative reactions and inflammation. With the rise in chronic diseases including diabetes, cardiovascular disease, chronic kidney disease, and neurological disorders, the need for managing AGEs and minimizing their downstream effects has increased substantially. Several drugs and supplements have emerged to curb the AGE formation process and even breakdown formed AGEs.

The Global Advanced Glycation End Products Market is estimated to be valued at US$ 3,469.95 Mn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030.

Key Takeaways

Key players operating in the Advanced Glycation End Products are Solage, Covalent-Biotics, DSM, Valenova Bio, and OPAL Pharma.

Growing prevalence of chronic diseases particularly diabetes and obesity is a major factor fueling the demand for AGE management drugs and supplements. High blood sugar and obesity accelerates AGE formation increasing risks of heart disease, kidney disease, and neurological disorders.

Various companies are strategizing global expansion to tap the potential offered by emerging markets in Asia Pacific and Latin America. With rising health awareness, increasing discretionary spending on healthcare, and high disease burden, these regions present immense opportunities for AGE management products.

Market key trends

One of the major trends in the Advanced Glycation End Products market is increasing research to develop preventive therapies. Currently, available therapies focus more on disease management but researchers are exploring ways to inhibit the initial stages of AGE formation and cross-linking. Natural compounds with antioxidant and anti-inflammatory properties are being studied for their potential to interrupt the glycation cascade and prevent downstream damage. With successful research outcomes, more preventive drugs and nutraceuticals are expected to enter the market.

Porter’s Analysis
Threat of new entrants: Low cost of entry for new entrants as technology is easily accessible. However, established brands have strong customer loyalty and distribution channel.
Bargaining power of buyers: Buyers have moderate bargaining power as there are few substitutes available and brand loyalty drives purchase decisions.
Bargaining power of suppliers: Suppliers have low to moderate bargaining power due to availability of substitutes and less differentiation in raw materials.
Threat of new substitutes: Threat of new substitutes is moderate as technology is advancing but brand loyalty makes adoption of substitutes difficult.
Competitive rivalry: Intense competition exists among key players to gain major market share through extensive R&D and new product launches.

The US market holds the largest share in the advanced glycation end products market in terms of value owing to rising healthcare expenditure and awareness regarding diabetes management. The continuous technological advancements in medical devices have significantly boosted the demand for advanced glycation end products in the country.

The Asia Pacific region is anticipated to be the fastest growing market for advanced glycation end products during the forecast period. This is attributed to the increasing geriatric population, improving healthcare infrastructure, and rising per capita income in emerging countries such as China and India. Moreover, growing medical tourism industry is attracting patients from developed nations to the region, thereby supporting the market growth of advanced glycation end products.

*Note:

  1. Source: Coherent Market Insights, Public sources, Desk research
  2. We have leveraged AI tools to mine information and compile it